Thursday, March 4, 2021
Home Life Style Health & Fitness Bharat Biotech Advises People Not To Take "Covaxin" in Case of Allergies,...

Bharat Biotech Advises People Not To Take “Covaxin” in Case of Allergies, Fever, Bleeding Disorder

Bharat Biotech reiterated that the Drugs Controller General of India (DCGI) had authorised the "restricted use of Covaxin under clinical trial mode"

Bharat Biotech, makers of India’s first indigenous vaccine for Covid-19, has advised people not to take ‘Covaxin’ if they have allergies, fever, bleeding disorder, are on blood thinners, immune-compromised, or are on medicines that affect the immune system.

The Hyderabad-based vaccine-maker, in a fact sheet for recipients and caregivers, said that even pregnant and nursing women should not take the vaccine. People who have taken another Covid-19 vaccine or are suffering from any other serious health-related issues should also not take Covaxin.

Bharat Biotech reiterated that the Drugs Controller General of India (DCGI) had authorised the “restricted use of Covaxin under clinical trial mode”.

“Individuals who are prioritised under the public health programme of the Health Ministry will be covered under this endeavour. Informing the individuals about the offer to vaccinate them with Covaxin will rest with the respective government programme officials. Those offered Covaxin at pre-specified booths will have the option to receive or reject the administration of the vaccine,” says the fact sheet that surfaced on Tuesday. Company sources told IANS that the fact sheet was issued last week.

Please Follow NewsGram on Facebook To Get Latest Updates!

“As with any new medicine, this vaccine will be closely monitored to allow quick identification of any new safety information,” said Bharat Biotech. Side effects can be reported to toll-free number 18001022245.

The vaccine-maker said that in phase 1 and 2 clinical trials, Covaxin has demonstrated the ability to produce antibodies against Covid-19. However, the clinical efficacy of Covaxin is yet to be established and it is still being studied in phase 3 clinical trial.

In phase 1 and 2 trials, 680 people were administered two doses each of Covaxin. The phase 3 clinical trial with 25,800 participants is on. The first dose was administered to them on January 6. In the ongoing clinical trial, Covaxin has shown to generate immunity following two doses given four weeks apart, the firm said.

Covaxin, which Bharat Biotech developed in collaboration with the Indian Council of Medical Research and National Institute of Virology, and ‘Covishield’, developed by Oxford University and pharmaceutical company AstraZeneca and manufactured by Serum Institute of India at Pune, have been cleared by the DCGI for emergency use. Both the vaccines are in use during the nationwide immunisation programme launched on January 16.

Medical, Syringe, Vaccination, Needle, Vaccine
Bharat Biotech, makers of India’s first indigenous vaccine for Covid-19, has advised people not to take ‘Covaxin’ if they have allergies, fever, bleeding disorder, are on blood thinners, immune-compromised, or are on medicines that affect the immune system. Pixabay

The move to include Covaxin even before the publication of data from its phase 3 trial had come under criticism from some quarters. However, the regulator had defended the decision by saying that both the vaccines were totally safe.

ALSO READ: Do Not Neglect Your Child! It May Put An Effect on His/Her Brain Functioning

Over 500 adverse reactions were reported from across the country during two days of immunisation. Two deaths were also reported but the government clarified that these were not related to vaccination.

Bharat Biotech said in case of any Serious Adverse Events (SAV), vaccine recipients will be provided medically recognised standards of care in government-designated and authorised centers/hospitals. Compensation for the serious adverse event will be paid by Bharat Biotech International Limited and if SAV is proved to be causally related to the vaccine. The compensation amount will be determined by the ICMR Central Ethics Committee, it added. (IANS)

STAY CONNECTED

19,120FansLike
362FollowersFollow
1,773FollowersFollow

Most Popular

Best Sites To Play Andar Bahar Online

By John Graham Playing Andar Bahar is fun, especially when playing on a user-friendly site. It’s a game where you play and win. Besides, it’s...

7 Tips On How To Always Wake Up On Time In College

By Grace Johnson Many students complain that waking up early to go to classes seems to be getting more and more difficult day by day....

US Based OAC To Make The World’s First Space Hotel

If you are a space enthusiast, there is more exciting news as a US-based space construction company, Orbital Assembly Corporation (OAC), is planning to...

Gut Instinct To Figure Out Between Fake And Genuine Reviews

While booking a hotel online, travelers should trust their gut instinct rather than relying on computer algorithms to figure out between fake and genuine...

Study: Customized Diets Could Be Key To Optimizing Mental Health

Lifestyle changes and customized diets could be key to optimizing mental health, a new study suggests. The study indicates that significant customized diets and...

Study: One In Four People, Maybe Living With Some Degree Of Hearing Loss By 2050

Nearly 2.5 billion people worldwide, or one in four people, maybe living with some degree of hearing loss by 2050, and at least 700...

Rare India: Commit To A Life That Puts Planet And People First

The Climate crisis is real, and the travel industry is affected in so many ways that there is an immediate need to address how...

World Wildlife Day: Here Are Some Wildlife Sanctuaries Worth Visiting

With millions of species breathing on earth, the world celebrates Wildlife Day today, March 3, to raise awareness of global flora and fauna. There...

Recent Comments